iTeos Therapeutics, Inc. (ITOS)
After hours:
| Previous close | 11.49 |
| Open | 11.72 |
| Bid | 11.62 x 200 |
| Ask | 11.68 x 100 |
| Day's range | 11.51 - 11.91 |
| 52-week range | 8.20 - 18.24 |
| Volume | |
| Avg. volume | 286,516 |
| Market cap | 419.358M |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Zacks
Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade
The consensus price target hints at a 243.4% upside potential for iTeos Therapeutics, Inc. (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks
Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 283.6% in iTeos Therapeutics, Inc. (ITOS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
